Trial Profile
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Angelman syndrome
- Focus Adverse reactions
- Acronyms ELARA
- Sponsors Ovid Therapeutics
- 28 Jul 2021 This trial has been completed in Netherlands , according to European Clinical Trials Database record.
- 15 Jun 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 07 May 2021 This trial has been suspended in Germany, according to European Clinical Trials Database record.